INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
10/06/2026
Voltar para busca
Dado oficial do USPTO
AYOXXA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
11/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
06/10/2017
Data de registro
26/03/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/10/2025
Última transação
11/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
BERLIN, JUSTIN E
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
AyoxxA Biosystems GmbH
Representantes
Joyce von Natzmer Agris & von Natzmer LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; veterinary pharmaceutical preparations for treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations; diagnostic agents for medical purposes; diagnostic agents for veterinary purposes; chemical and biochemical preparations for medical purposesfor treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; chemical and biochemical reagents for medical purposes; chemical and biochemical preparations for veterinary purposesfor treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations; chemical and biochemical reagents for veterinary purposes; chemical and biochemical preparations for pharmaceutical purposesfor treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseases; chemical and biochemical reagents for medical or veterinary pharmaceutical purposes; biological agents for laboratory analyses for medical purposespeptidesproteins and nucleic acids used as diagnostic agents for medical purposes; biological agents for laboratory analyses for veterinary purposespeptidesproteins and nucleic acids used as diagnostic agents for veterinary purposes; chemical and biochemical preparations and reagents for medical purposesfor use in DNA analyses; chemical and biochemical preparations for blood tests for medical purposes; chemical and biochemical reagents for blood tests for medical purposes; chemical and biochemical preparations for blood tests for veterinary purposes; chemical and biochemical reagents for blood tests for veterinary purposes; peptidesproteinsnucleic acids and other biomoleculescomplexes of these moleculesfor medical purposessynthetic or natural peptidesproteinsallergensmetabolites or nucleic acids for the treatment and prevention of cancertreatment and prevention of inflammatory diseasestreatment and prevention of autoimmune diseasestreatment and prevention of cardiovascular diseasestreatment and prevention of ophthalmic diseasestreatment and prevention of gastro-intestinal diseasestreatment and prevention of neurologic diseasesprotein arrays for medical diagnosis purposesnucleic acid sequences for medical diagnosis purposes; proteinsnucleic acids and other biomoleculescomplexes of these moleculesfor veterinary purposessynthetic or natural peptidesproteinsallergensmetabolites or nucleic acids for treatment of gastro-intestinal diseasestreatment of inflammatory diseasestreatment of ophthalmic diseasestreatment of mucosa irritations in animalsprotein arrays for veterinary diagnosis purposesnucleic acid sequences for veterinary diagnosis purposes; chemical and biochemical preparations and reagents for labelling of molecules for medical detection and monitoring purposes; chemical and biochemical preparations and reagents for labelling of molecules for veterinary detection and monitoring purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
C71T
CANCELLED SECTION 71
10/10/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
26/03/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
01/11/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/08/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
25/07/2019
FIMP
FINAL DISPOSITION PROCESSED
25/07/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/06/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
26/03/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/01/2019
PUBO
PUBLISHED FOR OPPOSITION
08/01/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/12/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/11/2018
DOCK
ASSIGNED TO EXAMINER
22/10/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/09/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/09/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/09/2018
RFNP
REFUSAL PROCESSED BY IB
06/04/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
22/03/2018
RFRR
REFUSAL PROCESSED BY MPU
22/03/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/03/2018
CNRT
NON-FINAL ACTION WRITTEN
21/03/2018
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
16/02/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/02/2018
CNRT
NON-FINAL ACTION WRITTEN
06/02/2018
DOCK
ASSIGNED TO EXAMINER
16/01/2018
MAFR
APPLICATION FILING RECEIPT MAILED
16/01/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/01/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/01/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace AYOXXA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.